Company: LENZ
Filing Date: 2025-04-04
Form Type: 8-K
Source: 0001628280-25-016824
Chunk: 0

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On April 4, 2025, LENZ Therapeutics, Inc. (the “ Company”) entered into a Sales Agreement (the “ Sales Agreement”) with TD Securities (USA) LLC (“ TD Cowen”) to sell shares of the Company’s common stock, par value $0.00001 per share (the “ Common Stock”), having aggregate sales proceeds of up to $150,000,000, from time to time, through an “at the market” offering program under which TD Cowen will act as sales agent.

Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number or dollar amount of shares to be issued, the time period during which sales are requested to be made, limitations on the number or dollar amount of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, TD Cowen may sell the shares by methods deemed to be an “at the market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. TD Cowen agreed to use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global Select Market. The Sales Agreement may be terminated by the Company upon ten days’ notice to TD Cowen for any reason or by TD Cowen upon ten days’ notice to the Company for any reason, or immediately under certain circumstances, including but not limited to the occurrence of a material adverse change in the Company.

The Sales Agreement provides that TD Cowen will be entitled to compensation for its services in an amount equal to up to 3.0% of the gross proceeds of all shares of Common Stock sold through TD Cowen under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement.

The shares will be issued pursuant to the Company’s shelf registration statement on Form S-3, including the prospectus supplement contained therein, filed with the Securities and Exchange Commission (the “ SEC”) on April 4, 2025 (the “ Registration Statement”), once the Registration Statement is declared effective by the SEC.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement